Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the α isoform

Cancer Research

Volumn 59, Issue 14, 1999, Pages 3442-3450

  Wessel, Irene ^a,b   Jensen, Lars H ^b,c   Jensen, Peter B ^b   Falck, Jacob ^a,b   Rose, Angela ^c   Roerth, Mikael ^b   Nitiss, John L ^c   Sehested, Maxwell ^a  

^a Rigshospitalet   (Denmark)

^b FINSEN LABORATORY   (Denmark)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 BIS(3,5 DIOXO 1 PIPERAZINYL)BUTANE; ACLARUBICIN; ADENOSINE TRIPHOSPHATASE; ADENOSINE TRIPHOSPHATE; AMSACRINE; CAMPTOTHECIN; CARMUSTINE; CISPLATIN; CYTARABINE; DAUNORUBICIN; DNA; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; ETOPOSIDE; FOSTRIECIN; MERBARONE; NOVOBIOCIN; NUCLEOTIDE; RAZOXANE; VINCRISTINE;

ARTICLE; BINDING SITE; CATALYSIS; CONTROLLED STUDY; DNA CLEAVAGE; DRUG RESISTANCE; DRUG SENSITIVITY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LUNG SMALL CELL CANCER; POINT MUTATION; PRIORITY JOURNAL; SACCHAROMYCES CEREVISIAE; SITE DIRECTED MUTAGENESIS;

ADENOSINE TRIPHOSPHATE; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; AMSACRINE; ANIMALS; ANTINEOPLASTIC AGENTS; BINDING SITES; CARCINOMA, SMALL CELL; CATALYSIS; CHO CELLS; CONSENSUS SEQUENCE; CRICETINAE; CRICETULUS; DNA DAMAGE; DNA MUTATIONAL ANALYSIS; DNA TOPOISOMERASES, TYPE II; DNA, NEOPLASM; DNA, SINGLE-STRANDED; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; ETOPOSIDE; HUMANS; LUNG NEOPLASMS; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; POINT MUTATION; PROTEIN ISOFORMS; RAZOXANE; RECOMBINANT FUSION PROTEINS; SACCHAROMYCES CEREVISIAE; STRUCTURE-ACTIVITY RELATIONSHIP; THIOBARBITURATES; TUMOR STEM CELL ASSAY;

EID: 0033565646     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Wang, J. C. DNA topoisomerases. Annu. Rev. Biochem., 65: 635-692, 1996.
2. Wang, J. C. Moving one DNA double helix through another by a type II DNA lopoisomerase: the story of a simple molecular machine. Q. Rev. Biophys., 31: 107-144, 1998.
3. Lindsley, J. E., and Wang, J. C. On the coupling between ATP usage and DNA transport by yeast DNA topoisomerase II. J. Biol. Chem., 268: 8096-8104, 1993.
4. Hammonds, T. R., and Maxwell, A. The DNA dependence of the ATPase activity of human DNA topoisomerase 11α. J. Biol. Chem., 272; 32696-32703, 1997.
5. Chen, A. Y., and Liu, L. F. DNA topoisomerases: essential enzymes and lethal targets. Annu. Rev. Pharmacol. Toxicol., 34: 191-218, 1994.
6. Wasserman, R. A., and Wang, J. C. Analysis of yeast DNA topoisomerase II mutants resistant to the antitumor drug amsacrine. Cancer Res., 54: 1795-1800, 1994.
7. Tanabe, K., Ikegami, Y., Ishida, R., and Andoh, T. Inhibition of topoisomserase II by antitumor agents bis(2,6-dioxopiperazine) derivatives. Cancer Res., 51: 4903-4908, 1991.
8. Ishida, R., Miki, T., Narita, T., Yui, R., Sato, M., Utsumi, K. R., Tanabe, K., and Andoh, T. Inhibition of intracellular topoisomerase II by antitumor bis(2,6-dioxopiperazine) derivatives: mode of cell growth inhibition distinct from that of cleavable complex-forming type inhibitors. Cancer Res., 51: 4909-4916, 1991.
9. Roca, J., Ishida, R., Berger, J. M., Andoh, T., and Wang, J. C. Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp. Proc. Natl. Acad. Sci. USA, 91: 1781-1785, 1994.
10. Roca, J., and Wang, J. C. DNA transport by a type II DNA topoisomerase: evidence in favor of a two-gate mechanism. Cell, 77: 609-616, 1994.
11. Sehested, M., Wessel, I., Jensen, L. H., Holm, B., Oliveri, R. S., Kenwrick, S., Creighton, A. M., Nitiss, J. L., and Jensen, P. B. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159; a Tyr49Phe mutation confers high level resistance to bisdioxopiperazines. Cancer Res., 58: 1460-1468, 1998.
12. Jensen, P. B., Christensen, I. J., Sehested, M., Hansen, H. H., and Vindeløv, L. Differential cytotoxicity of 19 anticancer agents in wild type and etoposide resistant small cell lung cancer cell lines. Br. J. Cancer, 67: 311-320, 1993.
13. Kohn, K. W., Ewig, R. A. G., Erickson, L. C., and Zwelling, L. A. Measurement of strand breaks and cross-links by alkaline elution. In: E. C. Friedberg and P. C. Hanawalt (eds.), DNA Repair: A Laboratory Manual of Research Techniques, pp. 379-401. New York: Marcel Dekker Inc., 1981.
14. 1492 in the COOH-terminal region of topoisomerase IIα in human small cell lung cancer cells selected for resistance to etoposide results in an extranuclear enzyme localization. Cancer Res., 57: 4451-4454, 1997.
15. Hsiung, Y., Jannatipour, M., Rose, A., McMahon, J., Duncan, D., and Nitiss, J. L. Functional expression of human topoisomerase IIα in yeast: mutations at amino acids 450 or 803 of topoisomerase IIα result in enzymes that can confer resistance to anti-topoisomerase II agents. Cancer Res., 56: 91-99, 1996.
16. Worland, S. T., and Wang, J. C. Inducible overexpression, purification, and active site mapping of DNA topoisomerase II from the yeast Saccharomyces cerevisiae. J. Biol. Chem., 264: 4412-4416, 1989.
17. Sahai, B. M., and Kaplan, J. G. A quantitative decatenation assay for type II topoisomerases. Anal. Biochem., 156: 364-379, 1986.
18. Jannatipour, M., Liu, X. Y., and Nitiss, J. L. The top2-5 mutant of yeast topoisomerase II encodes an enzyme resistant to etoposide and amsacrine. J. Biol. Chem., 268: 18586-18592, 1993.
19. Jensen, P. B., Sørensen B. S., Demant, E. J. F., Sehested, M., Jensen, P. S., Vindeløv, L., and Hansen, H. H. Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4′-(9-acridinylamino)methanesulfon-m-anisidide in human small cell lung cancer cell lines and on topoisomerase II-mediated DNA cleavage. Cancer Res., 50: 3311-3316, 1990.
20. Ishida, R., Hamatake, M., Wasserman, R. A., Nitiss, J. L., Wang, J. C., and Andoh, T. DNA topoisomerase II is the molecular target of bisdioxopiperazine derivatives ICRF-159 and ICRF-193 in Saccharomyces cerevisiae. Cancer Res., 55: 2299-2303, 1995.
21. Sato, M., Ishida, R., Narita, T., Kato, J. I., Ikeda, H., Fukazawa, H., and Andoh, T. Interaction of the DNA topoisomerase II catalytic inhibitor meso-2,3-bis(3,5 dioxopiperazine-1-yl)butane (ICRF-193), a bisdioxopiperazine derivative, with the conserved region(s) of eukaryotic but not prokaryotic enzyme. Biochem. Pharmacol., 54: 545-550, 1997.
22. Chang, S., Hu, T., and Hsieh, T. S. Analysis of a core domain in Drosophila DNA topoisomerase II. Targeting of an antitumor agent ICRF-159. J. Biol. Chem., 273: 19822-19828, 1998.
23. Sehested, M., Jensen, P. B., Sørensen, B. S., Holm, B., Friche, E., and Demant, E. J. F. Antagonistic effect of the cardioprotector (+)-1,2,-bis(3-5-dioxopiperazinyl-1-yl)propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and etoposide (VP-16). Biochem. Pharmacol., 46: 389-393, 1993.
24. Sehested, M., and Jensen, P. B. Mapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycle. Biochem. Pharmacol., 51: 879-886, 1996.
25. Holm, B., Jensen, P. B., and Sehested, M. ICRF-187 rescue in etoposide (VP-16) treatment in vivo. A model targeting high-dose topoisomerase II poisons to CNS tumors. Cancer Chemother. Pharmacol., 38: 203-209, 1996.
26. Holm, B., Sehested, M., and Jensen, P. B. Improved targeting of brain tumors using dexrazoxane rescue of topoisomerase II combined with supralethal doses of etoposide and teniposide. Clin. Cancer Res., 4: 1367-1373, 1998.
27. Yalowich, J. C., Thampatty, P., Allan, W. P., Chee, G., and Hasinoff, B. B. Acquired resistance to ICRF-187 (dexrazoxane) in a CHO cell line is associated with a point mutation in DNA topoisomerase IIα (topo II) and decreased drug-induced DNA-enzyme complexes. Proc. Am. Assoc. Cancer Res., 39: 375, 1998.
28. Berger, J. M., Gamblin, S. J., Harrison, S. C., and Wang, J. C. Structure and mechanism of DNA topoisomerase II. Nature (Lond.), 379: 225-232, 1996.
29. Walker, J. E., Saraste, M., Runswick, M. J., and Gay, N. J. Distantly related sequences in the α-and β-subunits of ATP synthase, myosin, kinases and other ATP-requiring enzymes and a common nucleotide binding fold. EMBO J., 1: 945-951, 1982.
30. Jackson, A. P., and Maxwell, A. Identifying the catalytic residue of the ATPase reaction of DNA gyrase. Proc. Natl. Acad. Sci. USA, 90: 11232-11236, 1993.
31. Smith, C. V., and Maxwell, A. Identification of a residue involved in transition-state stabilization in the ATPase reaction of DNA gyrase. Biochemistry, 37: 9658-9667, 1998.
32. Harkins, T. T., and Lindsley, J. E. Pre-steady-state analysis of ATP hydrolysis by Saccharomyces cerevisiae DNA topoisomerase II. 1. A DNA-dependent burst in ATP hydrolysis. Biochemistry, 37: 7292-7298, 1998.
33. Harkins, T. T., Lewis, T. J., and Lindsley, J. E. Pre-steady-state analysis of ATP hydrolysis by Saccharomyces cerevisiae DNA topoisomerase II. 2. Kinetic mechanism for the sequential hydrolysis of two ATP. Biochemistry, 37: 7299-7312, 1998.
34. Fortune, J. M., and Osheroff, N. Merbarone inhibits the catalytic activity of human topoisomerase IIα by blocking DNA cleavage. J. Biol. Chem., 273: 17643-17650, 1998.
35. Bugg, B. Y., Danks, M. K., Beck, W. T., and Suttle, D. P. Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposide. Proc. Natl. Acad. Sci. USA, 88: 7654-7658, 1991.
36. Danks, M. K., Schmidt, C. A., Deneka, D. A., and Beck, W. T. Increased ATP requirement for activity of and complex formation by DNA topoisomerase II from human leukemic CCRF-CEM cells selected for resistance to teniposide. Cancer Commun., 1: 101-109, 1989.
37. O'Dea, M. H., Tamura, J. K., and Gellert, M. Mutations in the B subunit of Escherichia coli DNA gyrase that affect ATP-dependent reactions. J. Biol. Chem., 271: 9723-9729, 1996.